Exelixis
Exelixis, Inc. is an American biotechnology company that focuses on the development of small molecule therapies for the treatment of cancer. The company is headquartered in Alameda, California.
History[edit | edit source]
Exelixis was founded in 1994 by Corey Goodman, George Scangos, and Stelios Papadopoulos. The company initially focused on model organism genetics to identify novel drug targets. Over time, Exelixis shifted its focus to the development of small molecule drugs for cancer treatment.
Products[edit | edit source]
Exelixis has developed several notable products, including:
- Cabozantinib - A small molecule inhibitor of multiple tyrosine kinases, used in the treatment of medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.
- Cobimetinib - A MEK inhibitor used in combination with vemurafenib for the treatment of BRAF V600E or V600K mutation-positive melanoma.
Research and Development[edit | edit source]
Exelixis continues to invest heavily in research and development, focusing on the discovery and development of new therapies for cancer. The company collaborates with various academic institutions and other biotechnology companies to advance its pipeline of investigational drugs.
Collaborations[edit | edit source]
Exelixis has established several strategic collaborations to enhance its research and development efforts. Notable collaborations include partnerships with Bristol-Myers Squibb, Roche, and Ipsen.
Corporate Governance[edit | edit source]
The company's leadership team includes experienced professionals from the biotechnology and pharmaceutical industries. The current CEO is Michael M. Morrissey, who has been with the company since 2000.
See also[edit | edit source]
Related Pages[edit | edit source]
 |
This biotechnology company-related article is a stub. |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD
